Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Silexion Therapeutics Corp (SLXN) had Consolidated Net Income/Loss of $-2.73M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-2.73M |
|
-- |
|
-- |
|
$2.75M |
|
$-2.75M |
|
$0.02M |
|
$-2.73M |
|
$-2.73M |
|
$-2.73M |
|
$-2.73M |
|
|
Consolidated Net Income/Loss |
$-2.73M |
$-2.73M |
|
$-2.75M |
|
$-2.75M |
|
3.23M |
|
3.23M |
|
$-0.85 |
|
$-0.85 |
|
| Balance Sheet Financials | |
$4.07M |
|
$0.02M |
|
$0.54M |
|
$4.60M |
|
$4.06M |
|
-- |
|
$0.25M |
|
$4.31M |
|
$0.29M |
|
$0.29M |
|
$0.29M |
|
3.40M |
|
| Cash Flow Statement Financials | |
$-3.65M |
|
$0.00M |
|
$0.08M |
|
$6.08M |
|
$2.50M |
|
$-3.58M |
|
$0.34M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.65M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-939.16% |
|
-939.17% |
|
-59.39% |
|
-939.18% |
|
$0.09 |
|
$-1.13 |
|
$-1.13 |
|